← All trials
NCT06316323
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2023
- Primary completion
- Sep 29, 2023
- Completion date
- Jan 26, 2024
- First posted
- Mar 18, 2024
- Last posted
- Mar 18, 2024
- Enrollment
- 49
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universiti Teknologi MaraLead sponsor
- Universiti Teknologi MaraSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.